Chemomab Therapeutics Ltd (CMMB)
$1.63
+0.06
(+3.82%)▲
Live
Performance
- $1.61$1.69$1.63
1.23%
Downside
Day's Volatility :4.73%
Upside
3.55%
- $0.42$2.55$1.63
74.23%
Downside
52 Weeks Volatility :83.53%
Upside
36.08%
Returns
| Period | Chemomab Therapeutics Ltd | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 35.34% | 3.6% | 0.0% |
6 Months | 137.91% | 10.2% | 0.0% |
1 Year | 89.16% | 19.6% | 0.0% |
3 Years | -85.89% | 16.8% | -23.0% |
Highlights
Market Capitalization | 24.1M |
Book Value | $0.70 |
Earnings Per Share (EPS) | -1.06 |
Wall Street Target Price | 8.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.18% |
Return On Equity TTM | -93.8% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -16.0M |
Diluted Eps TTM | -1.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.05 |
EPS Estimate Next Year | -0.04 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 431.9%
Technicals Summary
Sell
Neutral
Buy
Chemomab Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Chemomab Therapeutics Ltd | -0.95% | 137.91% | 89.16% | -85.89% | -99.72% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Chemomab Therapeutics Ltd | NA | NA | NA | -0.05 | -0.94 | -0.46 | NA | 0.7 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Chemomab Therapeutics Ltd | Buy | $24.1M | -99.72% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Chemomab Therapeutics Ltd
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 130.7%
Institutional Holdings
Company Information
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
Organization | Chemomab Therapeutics Ltd |
Employees | 0 |
CEO | Dr. Adi Mor George Ph.D. |
Industry | Healthcare |
